0002073993-25-000001.txt : 20251024 0002073993-25-000001.hdr.sgml : 20251024 20251024170707 ACCESSION NUMBER: 0002073993-25-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251024 DATE AS OF CHANGE: 20251024 EFFECTIVENESS DATE: 20251024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Antigenix Therapeutics, Inc. CENTRAL INDEX KEY: 0002073993 ORGANIZATION NAME: EIN: 995017042 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-562071 FILM NUMBER: 251416883 BUSINESS ADDRESS: STREET 1: 300 CARNEGIE CENTER, SUITE 150 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (317) 552-5240 MAIL ADDRESS: STREET 1: 300 CARNEGIE CENTER, SUITE 150 CITY: PRINCETON STATE: NJ ZIP: 08540 D 1 primary_doc.xml X0708 D LIVE 0002073993 Antigenix Therapeutics, Inc. 300 CARNEGIE CENTER, SUITE 150 PRINCETON NJ NEW JERSEY 08540 (317) 552-5240 DELAWARE None None Corporation true 2024 Christopher Whitfield 300 Carnegie Center, Suite 150 New Jersey NJ NEW JERSEY 08540 Executive Officer Director Chief Executive Officer Shaun Hawkins 300 Carnegie Center, Suite 150 New Jersey NJ NEW JERSEY 08540 Director Kwesi Frimpong-Boateng 300 Carnegie Center, Suite 150 New Jersey NJ NEW JERSEY 08540 Director Other Health Care Decline to Disclose 06b false 2025-10-22 false true false 0 8363695 3363695 5000000 false 17 0 0 0 false Antigenix Therapeutics, Inc. /s/ Christopher Whitfield Christopher Whitfield Chief Executive Officer 2025-10-24